Esperion Therapeutics, Inc. Announces Exercise of Underwriters' Over-Allotment Option for Initial Public Offering

July 11, 2013

After Esperion's June 26 IPO of 5M shares at $14/share, the company has exercised 750,000 of common stock for over-allotment. The IPO is expected to net $72.8M. Esperion is a clinical-stage company developing and commercializing first-in-class, oral, lo
More »

BioNano Genomics and New York Genome Center Enter Into a Strategic Collaboration

July 8, 2013

As part of the collaboration, NYGC has purchased an IrysTM System to provide their direct research community with the most advanced long-read commercial technology, which accurately detects genomic variation, to accelerate translational research.
More »

GI Dynamics, Inc. Announces Completion of A$57.5 Million Private Placement and Launch of Share Purchase Plan

July 2, 2013

GI Dynamics intends to use the funds for its U.S. pivotal clinical trial (The ENDO Trial) and for general purposes. GI Dynamics develops and markets (exUS) EndoBarrier®, a non-surgical, non-pharmaceutical device to treat type 2 diabetes and/or obesity.
More »